Latest Asx Limited News

ASX Limited reported robust first-half results with 11.2% revenue growth, while advancing a strategic reset in response to the ASIC Inquiry and pushing forward its technology modernization agenda.

ASX Limited reported robust half-year results with an 11.2% rise in operating revenue and a steady net profit, while advancing its technology upgrade and responding to regulatory scrutiny.

ASX Limited has announced a fully franked ordinary dividend of AUD 1.018 per share for the half-year ending December 2025, offering shareholders a dividend reinvestment plan with a 2.5% discount.

ASX Limited has posted a solid 8.3% increase in net profit for the half-year ending December 2025, while announcing a reduced dividend payout and the planned departure of its CEO. The company is navigating regulatory scrutiny and investing heavily in technology upgrades.

ASX Limited announces that CEO Helen Lofthouse will step down in May 2026, coinciding with the imminent go-live of the CHESS project’s first phase. The Board initiates a global search for new leadership to guide the next stage of transformation.

ASX Limited has updated its FY26 expense growth guidance upwards, reflecting increased investments in risk management and technology modernisation alongside ASIC Inquiry-related costs, while reporting strong unaudited 1H26 revenue growth.

Next Science Limited has applied for voluntary delisting from the ASX following the sale of nearly all its assets to OSARTIS GmbH. The company proposes a capital return to shareholders and intends to commence winding up after delisting.

Minbos Resources has obtained a crucial ASX waiver allowing it to issue shares under its Share Purchase Plan without the usual shareholder approval, aligning pricing with its recent Placement and aiming to maintain fairness among investors.

Following a critical ASIC Inquiry Interim Report, ASX has pledged a strategic reset including a $150 million capital charge and enhanced board independence to restore market confidence.

Algorae Pharmaceuticals has announced a non-renounceable Loyalty Options Offer to eligible shareholders, aiming to raise up to $337,678 before costs, with potential additional capital of $4.7 million if all options are exercised. The capital raise supports the company’s pharmaceutical and AI research and development ambitions.

ASX Limited reaffirms its FY26 expense growth guidance while detailing progress on its five-year transformation and addressing regulatory challenges. Strong FY25 financial results and a robust market pipeline underpin the company’s outlook.

Wellard Limited has formally requested to delist from the ASX following the sale of its final revenue-generating vessel, aiming to reduce costs and return excess cash to shareholders. The move awaits shareholder approval at the upcoming AGM.